Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2015 Jul 1;5:11629. doi: 10.1038/srep11629

Highly homologous proteins exert opposite biological activities by using different interaction interfaces

Anat Iosub Amir 1, Martijn van Rosmalen 1, Guy Mayer 1, Mario Lebendiker 2, Tsafi Danieli 2, Assaf Friedler 1,a
PMCID: PMC4486954  PMID: 26130271

Abstract

We present a possible molecular basis for the opposite activity of two homologues proteins that bind similar ligands and show that this is achieved by fine-tuning of the interaction interface. The highly homologous ASPP proteins have opposite roles in regulating apoptosis: ASPP2 induces apoptosis while iASPP inhibits it. The ASPP proteins are regulated by an autoinhibitory interaction between their Ank-SH3 and Pro domains. We performed a detailed biophysical and molecular study of the Pro – Ank-SH3 interaction in iASPP and compared it to the interaction in ASPP2. We found that iASPP Pro is disordered and that the interaction sites are entirely different: iASPP Ank-SH3 binds iASPP Pro via its fourth Ank repeat and RT loop while ASPP2 Ank-SH3 binds ASPP2 Pro via its first Ank repeat and the n-src loop. It is possible that by using different moieties in the same interface, the proteins can have distinct and specific interactions resulting in differential regulation and ultimately different biological activities.

Protein–protein interactions are responsible for many cellular processes and many diseases are the result of impaired protein-protein interactions. In many cases, proteins use homologous domains to mediate their interactions with their partners. There are many cases where despite the high homology in the structure, the biological activity of such domains is different and even opposite. Here we show that fine-tuning of the binding interface underlies the molecular mechanism of this differential activity. Our model system is the ASPP (apoptosis stimulating proteins of p53) protein family, which plays a key role in regulating apoptosis. ASPP2 and ASPP1 activate apoptosis, while iASPP inhibits it1,2,3,4,5. ASPP2 is frequently downregulated in human cancers while iASPP is upregulated. Misregulation of the ASPP proteins is tightly associated with the malignancy of the tumor and with poor prognosis of the patients1,6,7,8,9,10,11,12.iASPP was identified as RelA-associated inhibitor (RAI), a 351 residues protein that binds and inhibits the transcriptional activity of the NFκB subunit p6513. Later it was discovered that RAI is the C-terminal part of an 828 residues protein termed iASPP (inhibitory member of the ASPP family)14 (Fig. 1a). iASPP has other important roles in cell regulation like inhibition of cell senescence and keratinocytes autophagy15,16.

Figure 1. The ASPP protein family.

Figure 1

Open in a new tab

(a) All the ASPP protein family members contain a Proline rich (Pro) domain, four ankyrin repeats (Ank) and an SH3 domain. ASPP2 and ASPP1 also contain a putative α-helical domain at their N- termini. The N-terminal part of ASPP2 has the structure of a β-Grasp ubiquitin-like fold (UBL)19. The iASPP fragments used in this study are iASPP Pro and iASPP Ank-SH3; (b) Backbone alignment of the crystal structures of ASPP2 Ank-SH3 (920-1121), PDB:4A6356 (orange) and iASPP Ank-SH3 (607-828), PDB: 2VGE7 (red). The alignment shows the structure similarity between ASPP2 Ank-SH3 and iASPP Ank-SH3. Figure was made using Pymol (The PyMOL Molecular Graphics System, Version 1.3. Schrödinger, LLC).

The ASPP proteins share sequence and structural similarity at their C-termini, which contain four Ankyrin repeats and a Src Homology 3 (Ank-SH3) domains7,17 (Fig. 1a,b). The ASPP proteins also contain a proline rich (Pro) domain2,14. The 549 residues iASPP Pro is longer than the 226 residues ASPP2 Pro. We have previously shown that ASPP2 Pro is intrinsically disordered18. The iASPP N-terminal part of the Pro domain is responsible for its cytoplasmic localization14. ASPP2 contains an N-terminal domain with a ubiquitin like fold that iASPP lacks2,19.

The ASPP proteins interact with different apoptosis-related proteins such as the p53 protein family, Bcl2 and NFκB2,7,13,20,21,22,23,24. iASPP Pro interacts with iASPP Ank-SH3 in cells and phosphorylation of iASPP by B1/CDK1 on S84 and S113 inhibits this interaction25. Phosphorylation of iASPP results in its re-localization to the nucleus and inhibition of p53 activity. Inhibition of iASPP phosphorylation in melanoma cells restored p53 function and suppressed the melanoma growth25. ASPP2 is regulated by an interaction between its Ank-SH3 domains and Pro domain, which regulates the intermolecular interactions of ASPP2 with its different protein partners by an autoinhibitory mechanism18,26. The binding sites of p53, Bcl2 and NFκB to ASPP2 Ank-SH3 are different, while the binding sites of ASPP2 Pro to ASPP2 Ank-SH3 overlaps the binding sites to all three proteins27. Competition experiments showed that ASPP2 Pro competes with peptides from p53, Bcl2 and NFκB for binding ASPP2 Ank-SH318,26. In Helicobacter pylori - infected cells, H. pylori protein CagA binds ASPP2, which results in ASPP2 binding to p5328,29. In these cells the interaction of ASPP2 with p53 is inhibited in the presence of ASPP2 726-782, which is derived from ASPP2 Pro, possibly because of this regulatory mechanism30.

Intrinsically disordered proteins (IDPs) or regions (IDRs) are highly flexible and lack a defined 3D structure31,32. IDPs and IDRs play crucial roles in many cellular processes such as transcriptional regulation, translation, recognition and signal transduction31,32. IDPs and IDRs can bind their partners with high specificity but low affinity32 and their binding to their partners is often regulated by post translational modifications such as acetylation, phosphorylation and methylation31. In many proteins that are regulated by auto-inhibition, the inhibitory region is highly disordered and has many phosphorylation sites33.

Despite the sequential and structural homology between their Ank-SH3 domains, the ASPP proteins have opposite activities in regulating apoptosis. The N-terminal domain that is unique to ASPP2 is not responsible for this difference34,35. To gain insight into the molecular mechanism behind this difference, we performed a detailed biophysical and molecular study of the Pro – Ank-SH3 interaction in iASPP and compared it to the interaction in ASPP2. We developed new protocols for expressing and purifying iASPP Pro. Using biophysical and computational methods we show that iASPP Pro is disordered, like ASPP2 Pro, and that the purified iASPP Pro and iASPP Ank-SH3 interact with each other in vitro. Peptide array screening revealed the exact binding sites between the iASPP domains. Our results show that the Pro-binding regions in iASPP Ank-SH3 are different than the Pro-binding regions in ASPP2 Ank-SH318, revealing selectivity and specificity between the ASPP proteins. This sheds light on the molecular basis for the difference in activity between the ASPP proteins.

Results

Development of a new protocol protocol for the expression and purification of iASPP Pro

HLT-iASPP Pro was expressed in E.coli Rosetta2 (Novagen) as described in materials and methods. HLT-iASPP Pro initially showed a high tendency to aggregate. Following the screening of conditions as described in materials and methods36, aggregation was minimized in 50 mM phosphate buffer pH = 7, 300 mM NaCl, 10% glycerol and 0.001% Tween 20. HLT-iASPP Pro was purified in two steps, including affinity chromatography using a Nickel Sepharose column (Fig. 2a) followed by size exclusion chromatography (Fig. 2b). An imidazole gradient was used for eluting HLT-iASPP Pro from the Nickel column. HLT-iASPP Pro eluted in 100% elution buffer containing 300 mM Imidazole. Unspecific bound contaminations eluted in 10%–20% elution buffer. The 602 residues iASPP-Pro was expressed with it truncated forms. These impurities, which eluted with the full protein from the Nickel column, were separated from the full length protein by using size exclusion chromatography. The full protein eluted first from the size exclusion column and was successfully separated from its truncated forms. We did not cleave the HLT tag to avoid the aggregation of the protein. The final concentration of HLT-iASPP Pro was 15 μM.

Figure 2. Purification of HLT-iASPP Pro.

Figure 2

Open in a new tab

(a) Elution profile from the Nickel Sepharose column using imidazole gradient (green) as monitored by UV absorbance at 280 nm; (b) Elution profile from the size exclusion chromatography sephacryl S200 500 ml column as monitored by UV absorbance at 280 nm. Inset: Coomassie staining of the SDS-PAGE gel of the purified HLT-iASPP Pro collected from the size exclusion chromatography column, Mw = 75.9 kDa, marked with an arrow.

iASPP Pro is intrinsically disordered

To characterize the structural properties of iASPP Pro, we used a combination of computational and experimental tools. Several disorder prediction servers predicted iASPP Pro (iASPP 1-602) to be mostly disordered (Fig. 3a). The CD spectra of purified HLT-iASPP Pro (Fig. 3b) did not show any characteristic secondary structure, indicating intrinsic disorder. HLT-iASPP Pro (MW = 75.9 kDa) eluted in size exclusion chromatography experiments as a wide peak with an elution volume corresponding to a 250 kDa globular protein (Fig. 3c). This further indicates that iASPP Pro is disordered since disordered proteins elute earlier than globular proteins of the same MW, due to their extended unfolded nature. Our results imply that iASPP Pro is intrinsically disordered, like ASPP2 Pro.

Figure 3. iASPP Pro is intrinsically disordered.

Figure 3

Open in a new tab

(a) Disorder prediction of iASPP Pro (1-602). Black- residues predicted to be disordered. Each row represents a different server; (b) CD spectrum of HLT-iASPP Pro. The spectrum did not show any characteristic secondary structure; (c) Analytical size exclusion chromatography results for purified HLT-iASPP Pro. The calculated Mw is 75.9 kDa but the protein eluted at a volume corresponding to Mw of ~250 kDa, supporting that it is disordered.

iASPP Ank-SH3 binds iASPP Pro in vitro

After purifying the recombinant HLT-iASPP Pro and iASPP Ank-SH3 we tested whether the recombinant proteins interact using Nickel affinity pulldown assay. Nickel-NTA beads were incubated for one hour with HLT-iASPP Pro or with buffer or HLT alone. Then the beads were incubated with iASPP Ank-SH3 for two hours. After three washes the proteins were eluted from the Nickel-NTA beads. iASPP Ank-SH3 was retrieved by Nickel-NTA beads that were incubated with HLT-iASPP Pro but not by Nickel-NTA beads that were incubated with buffer or HLT (Fig. 4) indicating that both iASPP domains interact with each other.

Figure 4. HLT-iASPP Pro interacts with iASPP Ank-SH3 in vitro.

Figure 4

Open in a new tab

Nickel affinity pulldown of iASPP Ank-SH3 by HLT-iASPP Pro, SDS PAGE gel coomassie staining results. Nickel-NTA beads were incubated with HLT-iASPP Pro or with buffer or HLT fusion domain alone, for 1 h at 4 °C. The samples were centrifuged and then incubated with iASPP Ank-SH3 for 2 h at 4 °C. The samples were centrifuged again and the beads were washed 3 times. The beads were eluted by boiling them in SDS solution. Ank-SH3 eluted from the beads only in the presence of HLT-iASPP Pro.

Mapping the binding sites between the iASPP domains

To map the sites in the iASPP domains that mediate the interactions, HLT-iASPP Ank-SH3 was screened for binding an array comprising 79 partly overlapping 15-residue peptides derived from iASPP Pro37 (Table S1). HLT-iASPP Ank-SH3 bound 19 peptides with a strong signal (Table 1, Fig. 5a,c) at an ionic strength (IS) of 150 mM. The binding peptides were derived from iASPP Pro regions spanning residues 60-82, 132-186, 196-210, 308-370, 380-410, 484-498, 540-562, and 604-618. HLT-iASPP Pro was screened for binding an array comprising 24 partly overlapping 15-residue peptides derived from iASPP Ank-SH3 (Table S1). HLT-iASPP Pro bound three peptides derived from iASPP Ank-SH3 residues 739-753, 764-778, and 800-814 (Figs 5b–d, Table 2).

Table 1. The iASPP Ank-SH3 binding regions in iASPP Pro: peptide array results.

Peptide Spot iASPP Pro residues peptide sequence
A14 60–74 QAGPPSRPPRYSSSS
A15 68–82 PRYSSSSIPEPFGSR
A23 132–146 YGSLDRATSPRPRAF
B1 148–162 GAGSSLGRAPSPRPG
B2 156–170 APSPRPGPGPLRQQG
B4 172–186 PTPFDFLGRAGSPRG
B7 196–210 FFPERGPSPRPPATA
B21 308–322 TLPRNYKVSPLASDR
B23 324–338 SDAGSYRRSLGSAGP
C1 340-354 GTLPRSWQPVSRIPM
C2 348–362 PVSRIPMPPSSPQPR
C3 356–370 PSSPQPRGAPRQRPI
C6 380-394 NAFWEHGASRAMLPG
C7 388–402 SRAMLPGSPLFTRAP
C8 396–410 PLFTRAPPPKLQPQP
C19 484–498 VARPLSPTRLQPALP
D3 540–554 KKQYQQIISRLFHRH
D4 548–562 SRLFHRHGGPGPGGP
D11 604–618 SMEMRSVLRKAGSPR
Open in a new tab

Figure 5. The binding sites between the iASPP domains: peptide array screening.

Figure 5

Open in a new tab

(a) Binding of HLT-iASPP Ank-SH3 to an array of peptides derived from iASPP Pro at IS = 150 mM. Dark spots indicate binding peptides. For peptide sequences see Table 1; (b) Binding of HLT-iASPP Pro to an array of peptides derived from iASPP Ank-SH3. Dark spots indicate binding peptides. For peptide sequences see Table 2; (c) The binding interface between the iASPP domains: The HLT-iASPP Ank-SH3 binding regions in iASPP Pro are colored purple. The HLT-iASPP Pro binding regions in iASPP Ank-SH3 are colored green; (d) The iASPP Pro binding regions in iASPP Ank-SH3, labeled in green on the crystal structure of iASPP Ank-SH3. PDB: 2VGE. The figure was generated using PyMOL (The PyMOL Molecular Graphics System, Version 1.3. Schrödinger, LLC).

Table 2. The iASPP Pro binding regions in iASPP Ank-SH3: peptide array results.

Peptide Spot iASPP Ank-SH3 residues peptide sequence
E16 739–753 EGYADCATYLADVEQ
E19 764–778 YALWDYSAEFGDELS
E23 800–814 WAALHGQEGYVPRNY
Open in a new tab

We quantified the interactions of the iASPP Pro derived peptides with iASPP Ank-SH3 using fluorescence anisotropy. The two tightest binding peptides were iASPP 60-74, which bound iASPP Ank-SH3 with Kd of 35 ± 2 μM, and iASPP 540-562, which bound iASPP Ank-SH3 with Kd of 34 ± 2 μM (Fig. 6). iASPP Ank-SH3 binding to iASPP 132-146, iASPP 172-186, iASPP 396-410 and iASPP 484-498 was observed but was too weak to quantify. iASPP 68-82, iASPP 156-170, iASPP 196-210, iASPP 308-322 and iASPP 324-338 showed no binding to iASPP Ank-SH3. iASPP 83-90, which includes the iASPP phosphorylation site S8425, did not bind iASPP Ank-SH3 in the peptide array or in fluorescence anisotropy experiments. Altogether, our results indicate that different interfaces on the Ank-SH3 domains of the ASPP proteins mediate their interactions with their Pro domains (Fig. 7). Three main regions of iASPP Ank-SH3 interact with iASPP Pro. These regions include the fourth Ank repeat (iASPP 739-753), the RT loop (iASPP 764-778) and the C-terminal residues 800-814. On the other hand, we have previously shown that ASPP2 Ank-SH3 binds ASPP2 Pro through the first Ankyrin repeat (ASPP2 931-961) and the n-src loop (ASPP2 1083-1096)18.

Figure 6. Binding of iASPP Ank-SH3 to the FL-iASPP derived peptides.

Figure 6

Open in a new tab

Fluorescence anisotropy results: 250 μM iASPP Ank-SH3 were titrated into fluorescein labeled iASPP derived peptides. Kd for iASPP 60-74 was found to be 35 ± 2 μM (square) while Kd for iASPP 540-562 was found to be 34 ± 2 μM (triangle).

Figure 7. The Ank-SH3 domains of iASPP and ASPP2 bind their Pro domains through distinct interfaces.

Figure 7

Open in a new tab

iASPP Ank-SH3 (red) binds iASPP Pro using its fourth ankyrin repeat, RT loop and residues 800-814 while ASPP2 Ank-SH3 (orange) binds ASPP2 Pro via its first ankyrin repeat and n-src loop. Green-Pro binding regions. iASPP PDB: 2VGE, ASPP2 PDB: 4A63. All Figures were generated using PyMOL (The PyMOL Molecular Graphics System, Version 1.3. Schrödinger, LLC).

Discussion

Despite the sequential and structural homology between their Ank-SH3 and Pro domains, the ASPP proteins have opposite activities in regulating apoptosis. To gain insight into the molecular mechanism behind this difference, we performed a detailed biophysical and molecular study of the Pro – Ank-SH3 interaction in iASPP and compared it to the interaction in ASPP2. In order to enable these quantitative biophysical studies, we developed for the first time a protocol for expressing and purifying a stable recombinant full-length iASPP Pro at concentrations sufficient for biophysical studies. We also made some modifications to the known protocol for producing recombinant iASPP Ank-SH3, mainly using the HLT tag7. Having the two recombinant proteins in hand at high purity and concentrations enabled us to show that iASPP Pro is intrinsically disordered like ASPP2 Pro18. Unlike other IDPs, iASPP Pro does not mediate interactions with other partner proteins32.

The binding interface between the iASPP domains

Our results show that iASPP Ank-SH3 and the full iASPP Pro 1-602 interact in vitro. It was shown before that the interaction of iASPP Pro with iASPP Ank-SH3 in cells is inhibited by phosphorylation of iASPP Pro on S84 and S113 by B1/CDK125. However it is not clear from the cellular studies or from our in vitro studies if the interaction between the iASPP domains is intramolecular or intermolecular18,25. The fact that iASPP Pro is intrinsically disordered might support the intramolecular possibility because many proteins that are regulated by autoinhibitory mechanism have intrinsically disordered regulatory domains. Many of these regulatory domains undergo alternative splicing, such as in the ASPP proteins, and have many phosphorylation sites33,38. In any case, the final regulatory outcome is the same regardless of whether the domain-domain interaction is intramolecular or involves dimerization.

iASPP 1-478 and specifically iASPP 1-240 but not iASPP 249-482 were previously shown to bind iASPP Ank-SH3 in a pull down assay25. We further mapped this interaction using peptide arrays and identified the exact regions in iASPP Pro that bind iASPP Ank-SH3. The two tightest binding peptides were iASPP 60-74, which is derived from the binding region iASPP 1-240, with Kd of 35 ± 2 μM, and iASPP 540-562, which represents a previously unknown binding site for iASPP Ank-SH3 in iASPP Pro, with Kd of 34 ± 2 μM. iASPP 60-74 is located close to the iASPP phosphorylation sites, indicating possible regulation by phosphorylation. Other iASPP 1-240 derived peptides that bound iASPP Ank-SH3 in the peptide array are not derived from iASPP phosphorylation sites or the sequence between these two sites (Table 1). Peptides derived from iASPP 249-482, and specifically iASPP 308-410, also bound iASPP Ank-SH3 in the peptide array experiment (Table 1), but showed no binding or the binding was too weak to quantify. iASPP 616-623 is also a part of the interaction interface: it bound iASPP Ank-SH3 with a Kd of 45 μM in a previous ITC experiment7 and its slightly overlapping peptide iASPP 604-618 bound iASPP Ank-SH3 in our peptide array experiments. Altogether, the Ank-SH3 binding regions in iASPP Pro are spread along the full length disordered Pro domain. Two of the tightest binding peptides, iASPP 60-74 and iASPP 616-623, are located at the two termini of the Pro domain. The affinities of the peptides derived from the Pro domain to the Ank-SH3 domain are low, as is expected for disordered domains32,38. The affinity of SH3 domains to their proline rich ligands is also known to be weak39,40. Mutations in iASPP Ank-SH3 showed that iASPP Ank-SH3 N813 and Y814 and to a lesser extent T722 and L724 are important for binding iASPP 1-24025. Here we found that the peptide iASPP 800-814 that includes two of these residues bound iASPP Pro in the peptide array. iASPP 739-753, which is derived from the fourth ankyrin repeat, and iASPP 764-778, which is derived from the RT loop in the SH3 domain, also bound iASPP Pro.

The binding interfaces in iASPP vs. ASPP2

Comparing the Pro - Ank-SH3 interaction interfaces in iASPP and ASPP218 revealed distinct and specific binding sites, which are totally different from each other. iASPP Pro binds the fourth Ank repeat (iASPP 739-753), RT loop (iASPP 764-778) and C-terminal residues (iASPP 800-814) of iASPP Ank-SH3. ASPP2 Pro binds the first Ank-repeat (ASPP2 931-961) and n-src loop (ASPP2 1083-1096) of ASPP2 Ank-SH318 (Fig. 7). The interface in iASPP Pro that mediates the interaction with its Ank-SH3 domain is much larger than the corresponding interface in ASPP2 Pro, probably because iASPP Pro is more than twice longer than ASPP2 Pro.

Our results can explain previous data reported in the literature regarding the interactions of ASPP2 and iASPP with p53. Energy assessment for p53 Core domain (p53CD) complexes with the Ank-SH3 domains of ASPP2 and iASPP27 showed the complex of p53CD with iASPP Ank-SH3 had a higher interaction energy than the complex of p53CD with ASPP2 Ank-SH317. This indicates that the binding mode is indeed different. Previous NMR experiments showed that the SH3 domains of iASPP and ASPP2 have a very similar binding interface with the Proline rich and core domains of p53 (p53 Pro + CD), which includes both the RT and n-src loops, while ASPP2 interacts with p53 Pro + CD also via the loops between Ank repeats 2-3 and 3-441. The crystal structure of ASPP2 Ank-SH3 complex with p53CD shows that the fourth Ank repeat and the RT and n-src loops of ASPP2 mediate this interaction17. However, the ASPP2 derived n-src loop peptide bound p53CD much tighter than peptides derived from the fourth Ank repeat and the RT loop of ASPP242. Docking studies performed for the iASPP Ank-SH3 - p53CD complex showed that the interaction between them is mediated mostly by the RT loop of iASPP. Mutational studies based on these results showed that only mutations in the iASPP RT loop, but not mutations in the n-Src loop, abolished the inhibitory effect of iASPP Ank-SH3 on p53-mediated expression of apoptosis-related genes43. These results are in line with our previous results, showing that the n-Src loop but not the RT loop is the binding site of ASPP2 Ank-SH3 to its Pro domain, while it is the opposite for the iASPP Ank-SH3- Pro interaction. This may indicate that the n-Src loop is a general binding interface of ASPP2, while the RT loop is a general binding interface of iASPP.

The possible molecular basis for the opposite activity of iASPP and ASPP2

Previous studies performed in our lab suggested that an important parameter in the molecular basis for the different activity of the ASPP proteins is the different electrostatic potential of the surfaces of their Ank-SH3 domains. The binding interface of ASPP2 has a higher negative charge compared to its homologous surface in iASPP27. Examining the sequences of the ASPP proteins revealed that indeed the first Ank repeat and n-src loop of ASPP2 are more negatively charged than these areas in iASPP, while the fourth Ank repeat of iASPP is more negatively charged than this area in ASPP2. The RT loops of both ASPP proteins have the same charge, but there is a difference in the location of their negatively charged residues.

Other examples of highly homologous proteins that bind differentially to their ligands were reported. Sequence variability in the RT and n-src loops in SH3 domains can lead to binding specificity, for example the HIV-1 Nef protein interacts only with the SH3 domain of the Hck protein but not with similar src family members due to one different residue in its RT loop44. There are other examples of structurally homologous proteins that bind similar ligands in different ways, but the activity of the proteins is not opposite. For example the retinoid transport proteins bind and transport retinoids in different sub-cellular areas and tissues. Although they have very similar architectures they bind the retinoids in different ways45.

Our results suggest that fine-tuning of the interaction interface can lead to different and even opposite activities of highly homologous proteins. By using different moieties in the same interface, the proteins can have distinct and specific interactions resulting in differential regulation and ultimately different biological activities. Our results also shed light on the possible molecular basis for the difference in activity between the ASPP proteins, where iASPP is anti-apoptotic while ASPP2 is pro-apoptotic. The different binding interfaces to the regulatory Pro domains in these highly similar structures may be part of the reasons for the different biological activities. As misregulation of the ASPP proteins is responsible for many cancerous transformations, understanding the molecular basis for the opposite activity of the ASPP proteins will provide the basis for developing future anti-cancer lead compounds that inhibit iASPP or mimic the apoptotic activity of ASPP2.

Methods

Plasmids preparation

The plasmid containing iASPP 1-828 was a kind gift of Prof. Xin Lu, Ludwig Institute for Cancer Research, Oxford, UK. DNAs encoding fragments of iASPP were amplified by PCR using primers introducing an upstream EcoRI restriction site and a downstream NotIrestriction site: (1) iASPP Pro 1-602, 5´-GTGTACCGGAATTCAAGACAGCGAGGCATTCCAGAGC-3´, 5´-GTAAGAATGCGGCCGCCTACGGCTGCTCTGTGGGC-3´; (2) iASPP Ank-SH3 603-828, 5´-GTG TAC CGG AAT TCA ACA GAG CAT GGA GAT GCG CTC TG-3´, 5´-GTA AGA ATG CGG CCG CCT AGA CTT TAC TCC TTT GAG GCT TCA CCC TG-3´. PCR products were separated on 1% agarose gel and purified using GFXTm PCR DNA and gel band purification kit (Amersham). The PCR products were heated to 97 °C, cooled down to 37 °C and then cleaved by EcoRI and NotI (New England Biolabs) and purified again. The insert fragments were ligated (ligation master mix TAKARA) into the ampicillin resistant pET-Based vector pHis parallel 2HLT (HLT tag- The lipoyl domain fusion tag containing the N-terminus His tag and an optimized Tobacco Etch Virus (TEV) protease cleavage site36). The ligation reaction product was transformed into competent Escherichia coli Stable3 bacteria (Invitrogen) and bacterial colonies were screened for the presence of the gene using PCR. Positive colonies were further verified by sequencing. The analyzed sequence of the vector containing domains of the iASPP gene was compared and found identical to the iASPP sequence from Swiss-Prot entry Q8WUF5 (IASPP_HUMAN).

Protein expression and purification

HLT-iASPP Pro

was expressed in Escherichia coli Rosetta2 (Novagen). Bacteria were grown in 2xYT medium containing 1% glucose at 37 °C. Induction was performed at A600 nm = 0.6 with 0.4 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were harvested after 16 h of incubation at 17 °C. Bacterial cells expressing HLT-iASPP Pro were lysed using a Microfluidizer (Microfluidics). HLT-iASPP Pro showed a high tendency to aggregate. To overcome this, we screened different expression conditions, which included different buffers, NaCl concentrations and additives that included Arginine, Glutamate, Tween 20, Tween 80, zwitergent, trehalose and Trimethylamine N-oxide. Aggregation of HLT-iASPP Pro was minimized in phosphate buffer pH = 7, 300 mM NaCl, 10% glycerol and in the presence of 0.001% Tween 20. HLT-iASPP Pro was lysed in buffer A (50 mM Phosphate pH = 7.0, 0.3 M NaCl, 10% glycerol) containing 1% Tween20, lysozyme, DNase, 0.2 mM MgSO4, and 1:200 protease inhibitor P-8849 (Sigma) and purified using an Äkta Explorer FPLC system (GE Healthcare). The soluble fraction was purified using a Nickel Sepharose FF 4 ml column. Elution was performed using an imidzole gradient (Buffer A + 0.001% Tween 20 and 300 mM imidazole). HLT-iASPP Pro was further purified using size exclusion chromatography on a Sephacryl S200, 500 ml column. Elution was performed with buffer A + 0.001% Tween 20, which was also used as the storage buffer. The final concentration of HLT-iASPP Pro was 15 μM.

HLT-iASPP Ank-SH3

was expressed in E.coli HMS 174 (Novagen). Bacteria were grown in 2xYT medium containing 1% glucose at 37 °C. Induction was done at A600 nm = 0.6 with 0.1 mM IPTG for HLT-iASPP Ank-SH3. Cells were harvested after 16 h of incubation at 23 °C. iASPP Ank-SH3 was lysed using a Microfluidizer (Microfluidics) in buffer B (20 mM Tris-HCl pH = 8.0, 0.5 M NaCl, 10% glycerol, 5 mM β-mercaptoethanol) containing lysozyme, DNase, 0.2 mM MgSO4, and 1:200 protease inhibitor P-8849 (Sigma). iASPP Ank-SH3 was purified using an Äkta Explorer FPLC system (GE Healthcare). The soluble fraction was purified using a Nickel Sepharose FF 8 ml column. Elution was performed using an imidzole gradient. HLT-iASPP Ank-SH3 eluted in 100% elution buffer (containing buffer B + 250 mM imidazole). HLT-iASPP Ank-SH3 was further purified using size exclusion chromatography on a Sephacryl S100 column. Elution was performed with 20 mM Phosphate pH = 7.0, 0.15 M NaCl, 5 mM βMe, 10% glycerol and 0.02% NaN3, which was also used as the storage buffer. For cleaving the HLT tag from HLT-iASPP Ank-SH3, buffer B + 35 mM imidazole was used. HLT-iASPP Ank-SH3 was incubated for 16 h at 4 °C with Hisx6-TEV protease at a 20:1 (HLT-iASPP Ank-SH3:Hisx6-TEV) ratio. The Hisx6-tagged TEV protease, HLT-tag, impurities and any residual uncleaved HLT-iASPP Ank-SH3 were removed by an additional Nickel column step using Sepharose FF 4 ml column. The cleaved iASPP Ank-SH3 did not bind to the column and was further purified using size exclusion chromatography on a Sephacryl S100 column as described for HLT-iASPP Ank-SH3.

Disorder predictions

The following servers were used for disorder prediction of iASPP Pro: RONN46, IUPred47, DisEMBL48, Foldindex49, GlobPlot250, PrDOS51, Spritz52 and DisPROT53. In all cases, iASPP Pro 1-602 (Swiss-Prot entry Q8WUF5) was subjected to disorder prediction using default server parameters.

Circular Dichroism (CD)

CD spectra of HLT-iASPP Pro were recorded using a J-810 spectropolarimeter (Jasco) in a 0.1 cm quartz cuvette for far-UV CD spectroscopy, in a spectral range of 197 nm to 260 nm. 3 μM HLT- iASPP Pro was dissolved in 50 mM Phosphate buffer pH = 7.0, 300 mM NaCl, 10% glycerol, 0.02% NaN3 and 0.001% Tween 20.

Nickel affinity Pulldown assay

30 μl Nickel-NTA beads (Qiagen) were incubated with: (1) 500 μl buffer C (50 mM Phosphate buffer pH = 7.0, 300 mM NaCl, 10% glycerol, 0.02% NaN3 and 0.001% Tween 20); (2) 250 μl 31 μM HLT; (3) 2 ml 1.7 μM HLT-iASPP Pro (in buffer C) for 1 hour with gentle mixing at 4 °C and in the presence of 40 mM imidazole. The samples were centrifuged (2 min 3500 RPM), and washed with buffer C (5 min, 4 °C, gentle mixing). 80 μl of 80 μM iASPP Ank-SH3 in 20 mM Phosphate buffer pH = 7.0, 150 mM NaCl, 5mM βMe, 10% glycerol, 0.02% NaN3, 15 mM imidazole were added to the three samples. For diluting iASPP Ank-SH3, each sample was added to 1 ml 25 mM phosphate buffer pH = 7.0, 10% glycerol, 25 mM Imidazole and 100 mM NaCl. The Nickel-NTA beads and iASPP Ank-SH3 were gently mixed for 2 hours at 4 °C. The samples were centrifuged and the supernatants were collected. The samples were washed three times with 1 ml buffer C and the third washes were kept. The beads were eluted by boiling them in SDS sample solution. Samples were analyzed on a 10% SDS-PAGE gel.

Peptide array screening

The CelluSpotsTM peptide micro-arrays were synthesized by INTAVIS Bioanalytical Instruments AG, Köln, Germany. The 15 residue peptides were acetylated at their N-termini and attached to a cellulose membrane via their C termini through an amide bond. For screening the binding of the array to HLT-iASPP Ank-SH3 the array was first washed for 4 h at room temperature with 50 mM Tris-HCl pH = 8 at an ionic strength (IS) of 150 mM adjusted by NaCl, 0.05% Tween20 and 2.5% (W/V) skimmed milk (buffer D) for blocking unspecific binding. HLT-iASPP Ank-SH3 was dissolved in 20 mM Phosphate buffer pH = 7.0 IS = 150 mM, 5 mM βME, 10% glycerol and 0.02% NaN3 and 2.5% skimmed milk. 5 ml of 5 μM of the protein were incubated with the arrays at 4 °C with shaking overnight. After three washes with TBST, the array was incubated with anti His HRP conjugated antibody at room temperature for 1 hour. The antibody was dissolved in buffer D. Then the array was washed again three times with TBST. Immunodetection was performed using chemiluminiscence (ECL reagents). Peptide array screening for binding HLT-iASPP Pro was also preformed as above with change of the proteins buffer. HLT-iASPP Pro was dissolved in 50 mM Phosphate buffer pH = 7.0, 10% glycerol, 0.02% NaN3, 0.001% Tween 20, IS = 150 mM and 2.5% skimmed milk.

Peptide synthesis, labeling and purification

Peptides were synthesized on a Liberty Microwave Assisted Peptide Synthesizer (CEM) using standard Fmoc chemistry and HOBT/HBTU as coupling reagents. Trp was added at the N-termini of the peptides, when required, for measuring the peptide concentration using UV spectroscopy. The peptides were labeled with 5(6)-carboxyfluorescein at their N termini as described54 and cleaved from the resin as described55. The peptides were purified on a MERCK-Hitachi HPLC using a reverse-phase C8 preparative column with a gradient of ACN/TDW. MALDI TOF mass spectrometry and analytical HPLC were used to verify the identity and purity of the peptides.

Fluorescence anisotropy-binding studies

Binding of the iASPP Pro-derived peptides to iASPP Ank-SH3 was measured by fluorescence anisotropy using a PerkinElmer Life Sciences LS-50b spectrofluorimeter equipped with a Hamilton microlab M dispenser. Titration of iASPP Ank-SH3 into iASPP Pro derived fluorescein-labeled (FL) peptides was performed at 10 °C in 20 mM Hepes buffer, pH 7.3, 43 mM NaCl (total ionic strength = 50 mM), 10% glycerol and 5 mM β-mercaptoethanol. The excitation wavelength was set at 480 nm and the emission measured at 530 nm. The labeled peptide, dissolved in 1 ml buffer to a final concentration of 100 nM, was placed in the cuvette. 250 μM iASPP Ank-SH3 was placed in the dispenser and aliquots of 10–20 μl were added at 1.5 min intervals. The solution was then stirred for 30 sec, and the fluorescence and anisotropy were measured. Data were analyzed using the program Origin8 (OriginLab) and were fit to 1:1 binding model:

Inline graphic (R- measured fluorescence anisotropy, R0- anisotropy value corresponding to the free peptide, ∆R- amplitude of the fluorescence anisotropy change, [Protein]- protein concentration, Kd- dissociation constant).

Additional Information

How to cite this article: Iosub Amir, A. et al. Highly homologous proteins exert opposite biological activities by using different interaction interfaces. Sci. Rep. 5, 11629; doi: 10.1038/srep11629 (2015).

Supplementary Material

Supplementary Information
srep11629-s1.doc (33.5KB, doc)

Acknowledgments

A.F. is supported by grants from the Israel science foundation, the Israel cancer association, Israel cancer research foundation (ICRF) and the Minerva Center for Bio-hybrid complex systems. A.I. is supported by the Dalia and Dan Maydan Fellowship for advanced degree students at the Hebrew University of Jerusalem.

Footnotes

Author Contributions A.I. designed experiments, performed experiments, analyzed the data and wrote the manuscript. M.V.R. and G.M. designed and performed experiments. T.D. and M.L. provided help with protein expression and purification. A.F. supervised research, designed experiments, analyzed data and wrote the manuscript.

References

  1. Bergamaschi D. et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33, 162–7 (2003). [DOI] [PubMed] [Google Scholar]
  2. Samuels-Lev Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781–94 (2001). [DOI] [PubMed] [Google Scholar]
  3. Wang Y. et al. ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells. Cell Death Differ. 20, 525–34 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bergamaschi D. et al. ASPP1 and ASPP2: common activators of p53 family members. Mol. Cell. Biol. 24, 1341–1350 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cai Y., Qiu S., Gao X., Gu S.-Z. & Liu Z.-J. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes. Apoptosis 17, 777–83 (2012). [DOI] [PubMed] [Google Scholar]
  6. Liu Z.-J. et al. Downregulated mRNA expression of ASPP and the hypermethylation of the 5’-untranslated region in cancer cell lines retaining wild-type p53. FEBS Lett. 579, 1587–90 (2005). [DOI] [PubMed] [Google Scholar]
  7. Robinson R. A., Lu X., Jones E. Y. & Siebold C. Biochemical and structural studies of ASPP proteins reveal differential binding to p53, p63, and p73. Structure 16, 259–68 (2008). [DOI] [PubMed] [Google Scholar]
  8. Lossos I. S., Natkunam Y., Levy R. & Lopez C. D. Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk. Lymphoma 43, 2309–17 (2002). [DOI] [PubMed] [Google Scholar]
  9. Zhang X., Wang M., Zhou C., Chen S. & Wang J. The expression of iASPP in acute leukemias. Leuk. Res. 29, 179–83 (2005). [DOI] [PubMed] [Google Scholar]
  10. Jiang L. et al. iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe. Clin. Cancer Res. 17, 6924–33 (2011). [DOI] [PubMed] [Google Scholar]
  11. Liu Z. et al. Elevated expression of iASPP in head and neck squamous cell carcinoma and its clinical significance. Med. Oncol. 29, 3381–8 (2012). [DOI] [PubMed] [Google Scholar]
  12. Liu H., Wang M., Diao S., Rao Q. & Zhang X. siRNA-mediated down-regulation of iASPP promotes apoptosis induced by etoposide and daunorubicin in leukemia cells expressing wild-type p53. Leuk. Res. 33, 1243–1248 (2009). [DOI] [PubMed] [Google Scholar]
  13. Yang J., Hori M., Sanda T. & Okamoto T. Identification of a novel inhibitor of nuclear factor-κB, RelA-associated inhibitor. J. Biol. Chem. 274, 15662–70 (1999). [DOI] [PubMed] [Google Scholar]
  14. Slee E. a. et al. The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene 23, 9007–16 (2004). [DOI] [PubMed] [Google Scholar]
  15. Chikh A. et al. iASPP is a novel autophagy inhibitor in keratinocytes. J. Cell Sci. 127, 3079–93 (2014). [DOI] [PubMed] [Google Scholar]
  16. Notari M. et al. Inhibitor of apoptosis-stimulating protein of p53 (iASPP) prevents senescence and is required for epithelial stratification. Proc. Natl. Acad. Sci. USA 108, 16645–50 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Gorina S. & Pavletich N. P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001–5 (1996). [DOI] [PubMed] [Google Scholar]
  18. Rotem S. et al. The structure and interactions of the proline-rich domain of ASPP2. J. Biol. Chem. 283, 18990–9 (2008). [DOI] [PubMed] [Google Scholar]
  19. Tidow H., Andreeva A., Rutherford T. J. & Fersht A. R. Solution structure of ASPP2 N-terminal domain (N-ASPP2) reveals a ubiquitin-like fold. J. Mol. Biol. 371, 948–58 (2007). [DOI] [PubMed] [Google Scholar]
  20. Yang J. P. et al. NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. Oncogene 18, 5177–86 (1999). [DOI] [PubMed] [Google Scholar]
  21. Naumovski L. & Cleary M. The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. Mol. Cell. Biol. 16, 3884–3892 (1996). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Benyamini H. et al. A model for the interaction between NF-kappa-B and ASPP2 suggests an I-kappa-B-like binding mechanism. Proteins 77, 602–11 (2009). [DOI] [PubMed] [Google Scholar]
  23. Katz C. et al. Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2. Proc. Natl. Acad. Sci. USA 105, 12277–12282 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Iosub-Amir A. & Friedler A. Protein-protein interactions of ASPP2: an emerging therapeutic target. Medchemcomm 5, 1435–1443 (2014). [Google Scholar]
  25. Lu M. et al. Restoring p53 function in human melanoma cells by inhibiting MDM2 and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell 23, 618–33 (2013). [DOI] [PubMed] [Google Scholar]
  26. Rotem-Bamberger S., Katz C. & Friedler A. Regulation of ASPP2 interaction with p53 core domain by an intramolecular autoinhibitory mechanism. PLoS One 8, e58470 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Benyamini H. & Friedler A. The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins. J. Mol. Recognit. 24, 266–74 (2011). [DOI] [PubMed] [Google Scholar]
  28. Buti L. et al. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc. Natl. Acad. Sci. USA. 108, 9238–43 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Bonsor D. a. et al. Characterization of the translocation-competent complex between the Helicobacter pylori oncogenic protein CagA and the accessory protein CagF. J. Biol. Chem. 288, 32897–909 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nesic D., Buti L., Lu X. & Stebbins C. E. Structure of the Helicobacter pylori CagA oncoprotein bound to the human tumor suppressor ASPP2. Proc. Natl. Acad. Sci. USA 111, 1562–7 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Dyson H. J. & Wright P. E. Intrinsically unstructured proteins and their functions. Nat. Rev. Mol. Cell Biol. 6, 197–208 (2005). [DOI] [PubMed] [Google Scholar]
  32. Uversky V. & Dunker A. Understanding protein non-folding. Biochim. Biophys. Act 1804, 1231–1264 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Trudeau T. et al. Structure and intrinsic disorder in protein autoinhibition. Structure 21, 332–41 (2013). [DOI] [PubMed] [Google Scholar]
  34. Ao Y., Rohde L. H. & Naumovski L. p53-interacting protein 53BP2 inhibits clonogenic survival and sensitizes cells to doxorubicin but not paclitaxel-induced apoptosis. Oncogene 20, 2720–5 (2001). [DOI] [PubMed] [Google Scholar]
  35. Iwabuchi K. et al. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J. Biol. Chem. 273, 26061–8 (1998). [DOI] [PubMed] [Google Scholar]
  36. Lebendiker M. & Danieli T. Production of prone-to-aggregate proteins. FEBS Lett. 588, 236–46 (2014). [DOI] [PubMed] [Google Scholar]
  37. Katz C. et al. Studying protein-protein interactions using peptide arrays. Chem. Soc. Rev. 40, 2131–45 (2011). [DOI] [PubMed] [Google Scholar]
  38. Uversky V. N. MultIDIMensionality of IDIMs: intrinsic disorder in autoinhibition. Structure 21, 315–6 (2013). [DOI] [PubMed] [Google Scholar]
  39. Mayer B. J. SH3 domains: complexity in moderation. J. Cell Sci. 114, 1253–63 (2001). [DOI] [PubMed] [Google Scholar]
  40. Dalgarno D., Botfield M. & Rickles R. SH3 domains and drug design: ligands, structure, and biological function. Biopolymers 43, 383–400 (1997). [DOI] [PubMed] [Google Scholar]
  41. Ahn J., Byeon I.-J. L., Byeon C.-H. & Gronenborn A. M. Insight into the structural basis of pro- and antiapoptotic p53 modulation by ASPP proteins. J. Biol. Chem. 284, 13812–22 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Friedler A. et al. A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA 99, 937–42 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Tomoda K. et al. Molecular docking analysis of the protein-protein interaction between RelA-associated inhibitor and tumor suppressor protein p53 and its inhibitory effect on p53 action. Cancer Sci. 99, 615–22 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Lee C. H. et al. A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J. 14, 5006–15 (1995). [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Zhang Y.-R., Zhao Y.-Q. & Huang J.-F. Retinoid-binding proteins: similar protein architectures bind similar ligands via completely different ways. PLoS One 7, e36772 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Yang Z. R., Thomson R., McNeil P. & Esnouf R. M. RONN: the bio-basis function neural network technique applied to the detection of natively disordered regions in proteins. Bioinformatics 21, 3369–76 (2005). [DOI] [PubMed] [Google Scholar]
  47. Dosztányi Z., Csizmok V., Tompa P. & Simon I. IUPred: web server for the prediction of intrinsically unstructured regions of proteins based on estimated energy content. Bioinformatics 21, 3433–4 (2005). [DOI] [PubMed] [Google Scholar]
  48. Linding R. et al. Protein disorder prediction: implications for structural proteomics. Structure 11, 1453–9 (2003). [DOI] [PubMed] [Google Scholar]
  49. Prilusky J. et al. FoldIndex: a simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics 21, 3435–8 (2005). [DOI] [PubMed] [Google Scholar]
  50. Linding R., Russell R. B., Neduva V. & Gibson T. J. GlobPlot: Exploring protein sequences for globularity and disorder. Nucleic Acids Res. 31, 3701–8 (2003). [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Ishida T. & Kinoshita K. PrDOS: prediction of disordered protein regions from amino acid sequence. Nucleic Acids Res. 35, W460–4 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Vullo A., Bortolami O., Pollastri G. & Tosatto S. C. E. Spritz: a server for the prediction of intrinsically disordered regions in protein sequences using kernel machines. Nucleic Acids Res. 34, W164–8 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Sickmeier M. et al. DisProt: the Database of Disordered Proteins. Nucleic Acids Res. 35, D786–93 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Weber P. J., Bader J. E., Folkers G. & Beck-Sickinger A. G. A fast and inexpensive method for N-terminal fluorescein-labeling of peptides. Bioorg. Med. Chem. Lett. 8, 597–600 (1998). [DOI] [PubMed] [Google Scholar]
  55. Gabizon R. et al. Using peptides to study the interaction between the p53 tetramerization domain and HIV-1 Tat. Biopolymers 90, 105–16 (2008). [DOI] [PubMed] [Google Scholar]
  56. Canning P., von Delft F. & Bullock A. N. Structural basis for ASPP2 recognition by the tumor suppressor p73. J. Mol. Biol. 423, 515–27 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Information
srep11629-s1.doc (33.5KB, doc)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES